Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva receives FDA acceptance for Bio-T-Gel NDA filing
Bio-T-Gel, a treatment for low testosterone levels in males, was initially developed by BioSante Pharma, and then was licensed to Teva for further development. As per the licensing
Bio-T-Gel, a treatment for low testosterone levels in males, was initially developed by BioSante Pharma, and then was licensed to Teva for further development. As per the licensing
IRMS|360 is a fully interoperable, public health emergency response solution to connect disparate data systems into a single, secure enterprise database repository, providing real-time actionable intelligence from the
In the trial, the patients were titrated to an optimal dose of rotigotine (0.5-4.0 T mg/24h) and periodically evaluated for safety and efficacy. Of the 295 patients in
PRT-201 is an investigational recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) and arteriovenous graft (AVG) outcomes in patients requiring chronic
As per the agreement, Quest and Hemispherx will equally share the clinical trial’s expenses. Hemispherx will offer technical expertise and relevant data to support the regulatory process necessary
The collaboration is expected to deliver a drug candidate, a first in class humanised anti-midkine antibody, using Cellmid’s patented sequence and Antitope’s proprietary EpiScreen and Composite Human Antibody
4SC-202 is a benzamide type selective inhibitor of human class I histone deacetylases (HDAC) isoenzymes 1, 2 and 3. TOPAS is a mono-centric, single arm, open-label dose escalation
5N Plus deploys a range of proprietary and technologies to produce products which are used in a number of pharmaceutical, electronic and industrial applications. Following the acquisition, MCP
The company has submitted the application on the basis of positive results which it has witnessed form preclinical studies. The studies showed Alliqua’s hydrogel based patch technology successfully
Previously, Dimerix signed an agreement with Takeda on 15 April 2010. As per the terms of the agreement, Dimerix will continue using its GPCR-HIT platform and insights into